| Stage |
Risk |
Increased SCr 1.5–1.9 times baseline or GFR decrease >25% |
<0.5 ml/kg/h for 6–12 h |
1 |
Increased SCr 1.5–1.9 times baseline
OR
⩾0.3 mg/dl (⩾26.5 μmol/l) increase |
1 |
Increased SCr 1.5–1.9 times baseline (7 days)
OR
⩾0.3 mg/dl (⩾26.5 μmol/l) increase (48 h) |
| |
Injury |
2.0–2.9 times baseline or GFR decrease >50% |
<0.5 ml/kg/h for ⩾12 h |
2 |
Same as RIFLE minus eGFR criteria |
2 |
same as AKIN |
| |
Failure |
3.0 times baseline, GFR decrease >75%, or SCr ⩾4.0 mg/dl (354 μmol/l) with an acute rise of ⩾0.5 mg/dl (44 μmol/l) |
<0.3 ml/kg/h for ⩾24 h
OR
Anuria for ⩾12 h |
3 |
Same as RIFLE or on RRT. eGFR criteria removed |
3 |
3.0 times baseline,
OR
Increase in SCr ⩾4.0 mg/dl (354 μmol/l)
OR
Initiation of renal replacement therapy
OR
For <18 years, decrease in eGFR to <35 ml/min per 1.73 m2
|
| |
Loss |
Persistent ARF=complete loss of kidney function (need for dialysis) >4 weeks |
|
|
Notable differences:
(1) Addition of 0.3 mg/dl absolute change in SCr to increase diagnostic sensitivity
(2) eGFR criteria removed
(3) 48-h time window to ensure acuity (also allows for inpatient baseline values)
(4) Exclusion of Loss/ESKD categories as diagnostic criteria |
|
Notable differences:
(1) Time frame differences for absolute versus relative changes in serum creatinine
(2) 0.5 mg/dl increase for those with SCr ⩾4.0 mg/dl (354 μmol/l) no longer required if minimum AKI threshold met
(3) Inclusion of eGFR criteria for children |
| |
ESKD |
End-stage kidney disease (>3 months) |
|
|
|
|
|